DongKoo Bio & Pharma동구바이오제약
006620 · KOSDAQ · ₩006620 · 동구바이오제약
₩3,250▲ ₩120 (3.83%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩243B | ₩249B | ₩216B | ₩195B | ₩155B |
| Cost of sales | ₩98B | ₩97B | ₩83B | ₩77B | ₩63B |
| Gross profit | ₩144B | ₩152B | ₩132B | ₩118B | ₩92B |
| Operating income | ₩9.2B | ₩13B | ₩15B | ₩17B | ₩8.1B |
| Net income | ₩50B | ₩2B | ₩12B | ₩6.6B | ₩9.3B |
| Net income to shareholders | ₩50B | ₩2B | ₩12B | ₩6.6B | ₩9.3B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩336B | ₩244B | ₩191B | ₩172B | ₩155B |
| Current assets | ₩126B | ₩107B | ₩88B | ₩87B | ₩74B |
| Cash and equivalents | ₩22B | ₩25B | ₩16B | ₩13B | ₩20B |
| Total liabilities | ₩184B | ₩139B | ₩81B | ₩70B | ₩55B |
| Current liabilities | ₩137B | ₩115B | ₩73B | ₩66B | ₩50B |
| Borrowings | ₩128B | ₩85B | ₩42B | ₩33B | ₩23B |
| Total equity | ₩152B | ₩105B | ₩110B | ₩102B | ₩100B |
| Shareholders' equity | ₩152B | ₩105B | ₩110B | ₩102B | ₩100B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩4.3B | ₩17B | ₩3.6B | ₩17B | ₩18B |
| Capital spending | ₩18B | ₩22B | ₩14B | ₩5B | ₩4.3B |
| Free cash flow | −₩22B | −₩4.5B | −₩10B | ₩12B | ₩14B |
| Dividends paid | ₩3.2B | ₩3.3B | ₩3B | ₩2.8B | ₩943M |
Consolidated where available. Amounts in won.
Also known as: DongKoo Bio & Pharma / 동구바이오제약 / 006620 / KRX:006620
Source: KRX statistical information